Novo Nordisk A/S Successfully Completes Phase I Trial of its Proprietary Oral Insulin (NN1954) Using Merrion Pharmaceuticals GIPET® Technology

Merrion Pharmaceuticals plc (ESM: MERR), today announces that its partner, Novo Nordisk, successfully completed a single dose Phase I trial with a novel oral insulin (NN1954). Merrion Pharmaceuticals GIPET Technology was used in the formulation of NN1954.

The aim of this randomised, double-blind placebo and active controlled single ascending dose trial was to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect on blood glucose levels) of NN1954.

Under the terms of the license agreement entered into with Novo Nordisk in 2008 Merrion, receives payments on achievement of certain development, regulatory and sales milestones as well as royalties on sales.

Merrion's Chairman, Michael Donnelly, said "This is another step towards improving the management options for diabetes.  This type of ascending dose trial is a critical stage in the development of a new therapeutic. We continue to be encouraged with the commitment of Novo Nordisk to the incorporation of Merrion's GIPET technology in the plan to bring an oral insulin tablet to the market."

Investor Enquiries:

Merrion Pharmaceuticals Plc.
Michael Donnelly

T +353 1 642 3300
email: [email protected]

Davy Corporate Finance
Ivan Murphy
David Nangle

T +353 1 679 6363

Media Enquiries:

Slattery Communications
Conor Dempsey

T +353 86 247 9892
E-mail: [email protected]

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.